Access to Eloctate
On February 24, the CHS Board of Directors formally objected to the recent CBS decision to restrict access to Eloctate for children under 12 and called on the CBS to reverse its decision.
Access to Hemlibra
On February 18, the CHS responded to the CBS medical/scientific review and the CADTH economic analysis of Hemlibra (emicizumab) for patients with hemophilia A with and without inhibitors.
Hemophilia Today
Check out the latest issue of the CHS’ newsmagazine, Hemophilia Today, for information, current news and issues relevant to the bleeding disorder community.
Research
Are there inequities in access to care amongst certain groups of patients with bleeding disorders?
St. Michael’s Hospital is conducting a study on access to care, in collaboration with the Canadian Hemophilia Society. People 18 years and older with a bleeding disorder are being asked to consider participating.
CHS 2017 Annual Report
The year 2017 was a remarkable one. Together, we have made noteworthy advancements
towards our vision for the inherited bleeding disorder community.
Q&A about RFPs
We often receive questions about the tender process (RFP) for clotting factor concentrates. We produced a Q&A document which we hope will answer all your questions on the topic.
Recombinant factor concentrate charts
Please check out our updated charts listing the recombinant factor concentrates and their description.
